The  ||| S:0 E:4 ||| DT
endogenous  ||| S:4 E:15 ||| JJ
cardioprotection  ||| S:15 E:32 ||| NN
during  ||| S:32 E:39 ||| IN
reperfusion  ||| S:39 E:51 ||| NN
in  ||| S:51 E:54 ||| IN
acute  ||| S:54 E:60 ||| JJ
myocardial  ||| S:60 E:71 ||| NNS
infarction  ||| S:71 E:82 ||| VBP
A  ||| S:82 E:84 ||| DT
prompt  ||| S:84 E:91 ||| JJ
primary  ||| S:91 E:99 ||| JJ
percutaneous  ||| S:99 E:112 ||| JJ
coronary  ||| S:112 E:121 ||| JJ
intervention  ||| S:121 E:134 ||| NN
with  ||| S:134 E:139 ||| IN
aspiration  ||| S:139 E:150 ||| JJ
thrombectomy  ||| S:150 E:163 ||| NN
and  ||| S:163 E:167 ||| CC
subsequent  ||| S:167 E:178 ||| JJ
stent  ||| S:178 E:184 ||| JJ
implantation  ||| S:184 E:197 ||| NN
at  ||| S:197 E:200 ||| IN
the  ||| S:200 E:204 ||| DT
culprit  ||| S:204 E:212 ||| NN
lesion  ||| S:212 E:219 ||| VBZ
combined  ||| S:219 E:228 ||| VBN
with  ||| S:228 E:233 ||| IN
optimal  ||| S:233 E:241 ||| JJ
anti-platelet  ||| S:241 E:255 ||| JJ
and  ||| S:255 E:259 ||| CC
anti-thrombotic  ||| S:259 E:275 ||| JJ
pharmacotherapy  ||| S:275 E:291 ||| NN
is  ||| S:291 E:294 ||| VBZ
the  ||| S:294 E:298 ||| DT
safest  ||| S:298 E:305 ||| NN
and  ||| S:305 E:309 ||| CC
most  ||| S:309 E:314 ||| RBS
effective  ||| S:314 E:324 ||| JJ
reperfusion  ||| S:324 E:336 ||| JJ
strategy ||| S:336 E:344 ||| NN
.  ||| S:344 E:346 ||| .
Unfortunately ||| S:346 E:359 ||| RB
,  ||| S:359 E:361 ||| ,
this  ||| S:361 E:366 ||| DT
therapy  ||| S:366 E:374 ||| NN
does  ||| S:374 E:379 ||| VBZ
not  ||| S:379 E:383 ||| RB
guarantee  ||| S:383 E:393 ||| VB
always  ||| S:393 E:400 ||| RB
a  ||| S:400 E:402 ||| DT
good ||| S:402 E:406 ||| JJ
,  ||| S:406 E:408 ||| ,
long-term  ||| S:408 E:418 ||| JJ
clinical  ||| S:418 E:427 ||| JJ
outcome  ||| S:427 E:435 ||| NN
and  ||| S:435 E:439 ||| CC
left  ||| S:439 E:444 ||| VBD
ventricular  ||| S:444 E:456 ||| JJ
function  ||| S:456 E:465 ||| NN
recovery ||| S:465 E:473 ||| NN
.  ||| S:473 E:475 ||| .
Despite  ||| S:475 E:483 ||| IN
the  ||| S:483 E:487 ||| DT
unquestionable  ||| S:487 E:502 ||| JJ
benefit  ||| S:502 E:510 ||| NN
of  ||| S:510 E:513 ||| IN
reperfusion ||| S:513 E:524 ||| NN
,  ||| S:524 E:526 ||| ,
we  ||| S:526 E:529 ||| PRP
have  ||| S:529 E:534 ||| VBP
evidence  ||| S:534 E:543 ||| NN
that  ||| S:543 E:548 ||| IN
its  ||| S:548 E:552 ||| PRP$
initial  ||| S:552 E:560 ||| JJ
phase  ||| S:560 E:566 ||| NN
leads  ||| S:566 E:572 ||| VBZ
to  ||| S:572 E:575 ||| TO
additional  ||| S:575 E:586 ||| JJ
damage  ||| S:586 E:593 ||| NN
at  ||| S:593 E:596 ||| IN
the  ||| S:596 E:600 ||| DT
area  ||| S:600 E:605 ||| NN
at  ||| S:605 E:608 ||| IN
risk ||| S:608 E:612 ||| NN
,  ||| S:612 E:614 ||| ,
so  ||| S:614 E:617 ||| RB
the  ||| S:617 E:621 ||| DT
final  ||| S:621 E:627 ||| JJ
effect  ||| S:627 E:634 ||| NN
is  ||| S:634 E:637 ||| VBZ
the  ||| S:637 E:641 ||| DT
compromise  ||| S:641 E:652 ||| NN
between  ||| S:652 E:660 ||| IN
benefits  ||| S:660 E:669 ||| NNS
and  ||| S:669 E:673 ||| CC
destruction ||| S:673 E:684 ||| NN
,  ||| S:684 E:686 ||| ,
which  ||| S:686 E:692 ||| WDT
come  ||| S:692 E:697 ||| VBP
with  ||| S:697 E:702 ||| IN
the  ||| S:702 E:706 ||| DT
reperfusion  ||| S:706 E:718 ||| JJ
wavefront ||| S:718 E:727 ||| NN
.  ||| S:727 E:729 ||| .
Experimental  ||| S:729 E:742 ||| JJ
studies  ||| S:742 E:750 ||| NNS
suggest  ||| S:750 E:758 ||| VBP
that  ||| S:758 E:763 ||| DT
postconditioning  ||| S:763 E:780 ||| NN
with  ||| S:780 E:785 ||| IN
several  ||| S:785 E:793 ||| JJ
very  ||| S:793 E:798 ||| RB
brief  ||| S:798 E:804 ||| JJ
cycles  ||| S:804 E:811 ||| NNS
of  ||| S:811 E:814 ||| IN
ischaemia  ||| S:814 E:824 ||| JJ
alternating  ||| S:824 E:836 ||| NN
with  ||| S:836 E:841 ||| IN
reperfusion  ||| S:841 E:853 ||| NN
applied  ||| S:853 E:861 ||| VBD
immediately  ||| S:861 E:873 ||| RB
after  ||| S:873 E:879 ||| IN
relief  ||| S:879 E:886 ||| NN
of  ||| S:886 E:889 ||| IN
a  ||| S:889 E:891 ||| DT
prolonged  ||| S:891 E:901 ||| JJ
epicardial  ||| S:901 E:912 ||| JJ
occlusion  ||| S:912 E:922 ||| NN
is  ||| S:922 E:925 ||| VBZ
associated  ||| S:925 E:936 ||| VBN
with  ||| S:936 E:941 ||| IN
the  ||| S:941 E:945 ||| DT
infarct  ||| S:945 E:953 ||| JJ
size  ||| S:953 E:958 ||| NN
limitation ||| S:958 E:968 ||| NN
.  ||| S:968 E:970 ||| .
The  ||| S:970 E:974 ||| DT
cellular  ||| S:974 E:983 ||| JJ
protective  ||| S:983 E:994 ||| JJ
effect  ||| S:994 E:1001 ||| NN
of  ||| S:1001 E:1004 ||| IN
postconditioning  ||| S:1004 E:1021 ||| NN
seems  ||| S:1021 E:1027 ||| VBZ
to  ||| S:1027 E:1030 ||| TO
be  ||| S:1030 E:1033 ||| VB
related  ||| S:1033 E:1041 ||| VBN
to  ||| S:1041 E:1044 ||| TO
prevention  ||| S:1044 E:1055 ||| VB
of  ||| S:1055 E:1058 ||| IN
mitochondrial  ||| S:1058 E:1072 ||| FW
permeability  ||| S:1072 E:1085 ||| FW
transition  ||| S:1085 E:1096 ||| FW
pore  ||| S:1096 E:1101 ||| FW
activation ||| S:1101 E:1111 ||| FW
.  ||| S:1111 E:1113 ||| .
We  ||| S:1113 E:1116 ||| PRP
have  ||| S:1116 E:1121 ||| VBP
still  ||| S:1121 E:1127 ||| RB
to  ||| S:1127 E:1130 ||| TO
wait  ||| S:1130 E:1135 ||| VB
for  ||| S:1135 E:1139 ||| IN
confirmation  ||| S:1139 E:1152 ||| NN
of  ||| S:1152 E:1155 ||| IN
the  ||| S:1155 E:1159 ||| DT
clinical  ||| S:1159 E:1168 ||| JJ
effectiveness  ||| S:1168 E:1182 ||| NN
of  ||| S:1182 E:1185 ||| IN
both  ||| S:1185 E:1190 ||| DT
postconditionig  ||| S:1190 E:1206 ||| NN
as  ||| S:1206 E:1209 ||| IN
well  ||| S:1209 E:1214 ||| RB
as  ||| S:1214 E:1217 ||| IN
pharmacotherapy  ||| S:1217 E:1233 ||| NNS
that  ||| S:1233 E:1238 ||| WDT
mimics  ||| S:1238 E:1245 ||| VBZ
postconditioning  ||| S:1245 E:1262 ||| JJ
effects  ||| S:1262 E:1270 ||| NNS
( ||| S:1270 E:1271 ||| -LRB-
e.g.  ||| S:1271 E:1276 ||| NNP
with  ||| S:1276 E:1281 ||| IN
cyclosporine ||| S:1281 E:1293 ||| NN
)  ||| S:1293 E:1295 ||| -RRB-
in  ||| S:1295 E:1298 ||| IN
a  ||| S:1298 E:1300 ||| DT
randomised ||| S:1300 E:1310 ||| NN
,  ||| S:1310 E:1312 ||| ,
multicenter  ||| S:1312 E:1324 ||| JJ
clinical  ||| S:1324 E:1333 ||| JJ
trial  ||| S:1333 E:1339 ||| NN
with  ||| S:1339 E:1344 ||| IN
properly  ||| S:1344 E:1353 ||| RB
designed  ||| S:1353 E:1362 ||| VBN
endpoint ||| S:1362 E:1370 ||| NN
.  ||| S:1370 E:1372 ||| .
To  ||| S:1372 E:1375 ||| TO
date ||| S:1375 E:1379 ||| NN
,  ||| S:1379 E:1381 ||| ,
most  ||| S:1381 E:1386 ||| RBS
clinically  ||| S:1386 E:1397 ||| RB
tested  ||| S:1397 E:1404 ||| VBN
agents  ||| S:1404 E:1411 ||| NNS
that  ||| S:1411 E:1416 ||| IN
induced  ||| S:1416 E:1424 ||| JJ
endogenous  ||| S:1424 E:1435 ||| NNS
cardioprotection  ||| S:1435 E:1452 ||| VBP
such  ||| S:1452 E:1457 ||| JJ
as  ||| S:1457 E:1460 ||| IN
adenosine ||| S:1460 E:1469 ||| NN
,  ||| S:1469 E:1471 ||| ,
erythropoietin ||| S:1471 E:1485 ||| NN
,  ||| S:1485 E:1487 ||| ,
protein  ||| S:1487 E:1495 ||| FW
kinase  ||| S:1495 E:1502 ||| FW
C-Î´  ||| S:1502 E:1506 ||| FW
inhibitor ||| S:1506 E:1515 ||| FW
,  ||| S:1515 E:1517 ||| ,
atrial  ||| S:1517 E:1524 ||| FW
natriuretic  ||| S:1524 E:1536 ||| FW
peptide ||| S:1536 E:1543 ||| FW
,  ||| S:1543 E:1545 ||| ,
atorvastatin  ||| S:1545 E:1558 ||| NN
and  ||| S:1558 E:1562 ||| CC
nicorandil  ||| S:1562 E:1573 ||| NNS
were  ||| S:1573 E:1578 ||| VBD
failed  ||| S:1578 E:1585 ||| VBN
to  ||| S:1585 E:1588 ||| TO
reduce  ||| S:1588 E:1595 ||| VB
infarct  ||| S:1595 E:1603 ||| JJ
size ||| S:1603 E:1607 ||| NN
.  ||| S:1607 E:1609 ||| .
Time  ||| S:1609 E:1614 ||| NN
will  ||| S:1614 E:1619 ||| MD
tell  ||| S:1619 E:1624 ||| VB
whether  ||| S:1624 E:1632 ||| IN
postconditioning  ||| S:1632 E:1649 ||| NN
and  ||| S:1649 E:1653 ||| CC
therapy  ||| S:1653 E:1661 ||| NN
that  ||| S:1661 E:1666 ||| IN
it  ||| S:1666 E:1669 ||| PRP
mimics  ||| S:1669 E:1676 ||| VBZ
meet  ||| S:1676 E:1681 ||| VB
expectation  ||| S:1681 E:1693 ||| NN
and  ||| S:1693 E:1697 ||| CC
find  ||| S:1697 E:1702 ||| VB
place  ||| S:1702 E:1708 ||| NN
in  ||| S:1708 E:1711 ||| IN
the  ||| S:1711 E:1715 ||| DT
recommendations  ||| S:1715 E:1731 ||| NNS
concerning  ||| S:1731 E:1742 ||| VBG
management  ||| S:1742 E:1753 ||| NN
of  ||| S:1753 E:1756 ||| IN
acute  ||| S:1756 E:1762 ||| JJ
myocardial  ||| S:1762 E:1773 ||| JJ
infarction ||| S:1773 E:1783 ||| NN
.  ||| S:1783 E:1785 ||| .
Kardiol  ||| S:1785 E:1793 ||| NNP
Pol  ||| S:1793 E:1797 ||| NNP
2011 ||| S:1797 E:1801 ||| CD
;  ||| S:1801 E:1803 ||| :
69 ||| S:1803 E:1805 ||| CD
,  ||| S:1805 E:1807 ||| ,
supl ||| S:1807 E:1811 ||| NN
.  ||| S:1811 E:1813 ||| .
III ||| S:1813 E:1816 ||| NNP
:  ||| S:1816 E:1818 ||| :
67-74 ||| S:1818 E:1823 ||| CD
.  ||| S:1823 E:1825 ||| .
